Addex Therapeutics ADXN Insider Ownership

NASDAQ ADXN
$3.61 -0.09 (-2.43%)
At close: Sep 9, 2026 · 4:00 PM EDT

Insider Holdings by Owner

22.25Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026
Insider Ownership
—
share count not reported for this filer set
Shares Held by Insiders
22.25Mn
filed for Sep 2026
Shares Outstanding
—
not reported
Direct Holdings
22.25Mn
Indirect: 0
Net Shares Traded (QoQ)
0
no net change in Sep 2026
Insiders Holding Shares
7
with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding
Latest —
Average ownership —
Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold
Latest quarter —
Net over range —
Buying quarters —
Form 4 Holdings

Insiders Holding ADXN

Insiders 7
Shares held 22.25Mn
Of outstanding —
# Insider Position Direct Indirect Total Share of Insiders Last Filed
1 Timothy Mark Dyer Chief Executive Officer 16,848,979 0 16,848,979 75.7% 04 Sep, 2026
2 Vincent Michael Lawton Director 2,507,987 0 2,507,987 11.3% 04 Sep, 2026
3 Raymond George Hill Director 1,365,532 0 1,365,532 6.1% 04 Sep, 2026
4 Roger Mills Chief Medical Officer 785,976 0 785,976 3.5% 04 Sep, 2026
5 Mikhail Kalinichev Head Of Translational Science 306,765 0 306,765 1.4% 04 Sep, 2026
6 Jason Raleigh Nunn Director 219,561 0 219,561 1.0% 04 Sep, 2026
7 Isaac Manke Director 219,561 0 219,561 1.0% 04 Sep, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

44 Insider Transactions

Source SEC Form 4
Latest quarter Sep 2026
Download Data
Date Insider Position Transaction Shares Price Value Shares Held After Ownership
02 Sep, 2026 Raymond George Hill Director Disposed D 1,365,532 $0.00 $0 0 Direct
02 Sep, 2026 Lenaic Nathanael Teyssedou Principal Accounting Officer Disposed D 37,770 $0.00 $0 565,138 Direct
02 Sep, 2026 Jason Raleigh Nunn Director Disposed D 219,561 $0.00 $0 0 Direct
02 Sep, 2026 Vincent Michael Lawton Director Disposed D 2,507,487 $0.00 $0 500 Direct
02 Sep, 2026 Roger Mills Chief Medical Officer Disposed D 392,837 $0.00 $0 393,139 Direct
02 Sep, 2026 Timothy Mark Dyer Chief Executive Officer Disposed D 16,413,787 $0.00 $0 435,192 Direct
02 Sep, 2026 Isaac Manke Director Disposed D 219,561 $0.00 $0 0 Direct
02 Sep, 2026 Mikhail Kalinichev Head Of Translational Science Disposed D 306,765 $0.00 $0 0 Direct
02 Sep, 2026 Vincent Michael Lawton Director Acquired A 2,507,487 $0.00 $0 2,507,987 Direct
02 Sep, 2026 Timothy Mark Dyer Chief Executive Officer Acquired A 16,413,787 $0.00 $0 16,848,979 Direct
02 Sep, 2026 Mikhail Kalinichev Head Of Translational Science Acquired A 306,765 $0.00 $0 306,765 Direct
02 Sep, 2026 Raymond George Hill Director Acquired A 1,365,532 $0.00 $0 1,365,532 Direct
02 Sep, 2026 Isaac Manke Director Acquired A 219,561 $0.00 $0 219,561 Direct
02 Sep, 2026 Roger Mills Chief Medical Officer Acquired A 392,837 $0.00 $0 785,976 Direct
02 Sep, 2026 Lenaic Nathanael Teyssedou Principal Accounting Officer Acquired A 37,770 $0.00 $0 602,908 Direct
02 Sep, 2026 Jason Raleigh Nunn Director Acquired A 219,561 $0.00 $0 219,561 Direct
02 Sep, 2026 Mikhail Kalinichev Head Of Translational Science Disposed D 200,000 $0.00 $0 0 Direct
02 Sep, 2026 Roger Mills Chief Medical Officer Disposed D 50,000 $0.00 $0 0 Direct
02 Sep, 2026 Isaac Manke Director Disposed D 50,000 $0.00 $0 0 Direct
02 Sep, 2026 Lenaic Nathanael Teyssedou Principal Accounting Officer Disposed D 59,530 $0.00 $0 543,378 Direct